论文部分内容阅读
日前,意大利40个血液病研究中心和德国27个类似机构合作,以150多名急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)人为研究对象,其中各一半的病人分别接受靶向药物治疗和化疗。结果显示,靶向药物治疗急性早幼粒细胞白血病的生存率高于结合药物的化疗。
A total of more than 150 human acute promyelocytic leukemia (APL) human studies have been conducted in cooperation with 27 similar institutions in Germany and 40 of the 40 hematological research centers in Italy have recently received targeted drug therapy Chemotherapy. The results showed that the targeted drug treatment of acute promyelocytic leukemia survival rate is higher than the combined drug chemotherapy.